WO2005058813A3 - Thiodiazolidinedione, oxazolidinedione and diazolidinedione derivatives and their use as antidiabetic agents - Google Patents

Thiodiazolidinedione, oxazolidinedione and diazolidinedione derivatives and their use as antidiabetic agents Download PDF

Info

Publication number
WO2005058813A3
WO2005058813A3 PCT/IB2004/004143 IB2004004143W WO2005058813A3 WO 2005058813 A3 WO2005058813 A3 WO 2005058813A3 IB 2004004143 W IB2004004143 W IB 2004004143W WO 2005058813 A3 WO2005058813 A3 WO 2005058813A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
compounds
diseases
disclosed
conditions
Prior art date
Application number
PCT/IB2004/004143
Other languages
French (fr)
Other versions
WO2005058813A2 (en
Inventor
Jitendra A Sattigeri
Mohammad Salman
Original Assignee
Ranbaxy Lab Ltd
Jitendra A Sattigeri
Mohammad Salman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Jitendra A Sattigeri, Mohammad Salman filed Critical Ranbaxy Lab Ltd
Publication of WO2005058813A2 publication Critical patent/WO2005058813A2/en
Publication of WO2005058813A3 publication Critical patent/WO2005058813A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are alkynyl derivatives, which have PPAR agonist activity, and can be used as antidiabetic compounds. Compounds disclosed herein can be used for the treatment of diabetes and diabetes-associated complications, to diseases and conditions in which insulin resistance is a pathophysiological mechanism, and to diseases or conditions such as Type II diabetes, dyslipidaemia, hypertension, coronary heart disease, cardiovascular disease, atherosclerosis, nephrosclerosis, polycystic ovarian syndrome, eating disorders, diabetes nephropathy, glomerulonephritis, glomerularsclerosis, nephrotic syndrome, psoriasis, obesity or dementia. Compounds disclosed herein also can inhibit aldose reductase. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and methods for treating diabetes mellitus and diseases and conditions mediated through insulin resistance are provided.
PCT/IB2004/004143 2003-12-17 2004-12-15 Thiodiazolidinedione, oxazolidinedione and diazolidinedione derivatives and their use as antidiabetic agents WO2005058813A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53033403P 2003-12-17 2003-12-17
US60/530,334 2003-12-17

Publications (2)

Publication Number Publication Date
WO2005058813A2 WO2005058813A2 (en) 2005-06-30
WO2005058813A3 true WO2005058813A3 (en) 2005-08-25

Family

ID=34700125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/004143 WO2005058813A2 (en) 2003-12-17 2004-12-15 Thiodiazolidinedione, oxazolidinedione and diazolidinedione derivatives and their use as antidiabetic agents

Country Status (1)

Country Link
WO (1) WO2005058813A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100331A2 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Antidiabetic agents
WO2009104200A1 (en) * 2008-02-21 2009-08-27 Biocon Limited A method for preparation of thiazolidinedione derivatives

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5532256A (en) * 1994-05-18 1996-07-02 American Home Products Corporation New azolidinediones and thiadiazolidinediones as antihyperglycemic agents
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5910592A (en) * 1992-09-05 1999-06-08 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
US5965589A (en) * 1994-08-10 1999-10-12 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
WO2001014349A1 (en) * 1999-08-23 2001-03-01 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5910592A (en) * 1992-09-05 1999-06-08 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
US5532256A (en) * 1994-05-18 1996-07-02 American Home Products Corporation New azolidinediones and thiadiazolidinediones as antihyperglycemic agents
US5965589A (en) * 1994-08-10 1999-10-12 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
WO2001014349A1 (en) * 1999-08-23 2001-03-01 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
EP1213287A1 (en) * 1999-08-23 2002-06-12 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives

Also Published As

Publication number Publication date
WO2005058813A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
Gupta et al. Synthesis and pharmacological evaluation of substituted 5-[4-[2-(6, 7-dimethyl-1, 2, 3, 4-tetrahydro-2-oxo-4-quinoxalinyl) ethoxy] phenyl] methylene] thiazolidine-2, 4-dione derivatives as potent euglycemic and hypolipidemic agents
EP2289868B1 (en) Carboxylic acid compound
US20170266245A1 (en) Hydrogenation of cannabis oil
WO2006066747A8 (en) 4-aminopiperidine derivatives
Pathak et al. Synthesis and biological evaluation of substituted 4, 6-diarylpyrimidines and 3, 5-diphenyl-4, 5-dihydro-1H-pyrazoles as anti-tubercular agents
WO2001012187A3 (en) Benzoic acid derivatives and their use as ppar receptor agonists
TW400330B (en) Novel thiazolidine-2, 4-dione, substitute, the manufacture method and the pharmaceutical compositions therefof
TW200503994A (en) Organic compounds
WO2008055940A3 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
NO20074117L (en) Methods and compositions for treating diabetes, metabolic diseases and conditions
Singh et al. Thiazole derivatives in medicinal chemistry: Recent advancements in synthetic strategies, structure activity relationship and pharmacological outcomes
Yanagisawa et al. Novel oximes having 5-benzyl-2, 4-thiazolidinedione as antihyperglycemic agents: synthesis and structure–activity relationship
WO2000071540A1 (en) Hydrochloride of fused-heterocycle compound
JP2012522748A5 (en)
NO20054798L (en) Processed fat preparation for the prevention / improvement of lifestyle-related diseases
BRPI0407180A (en) Compound, pharmaceutical composition, methods for modulating a peroxisome proliferator-activated receptor, for treating or preventing a disease or condition, for lowering blood glucose in a mammal, for treating or preventing diabetes mellitus, cardiovascular disease, and syndrome x in a mammal. , and, use of a compound
TW200741205A (en) A novel physiologically active compound, NESFATIN, related compounds thereof and their use
Azam et al. Structure-based design, synthesis and molecular modeling studies of thiazolyl urea derivatives as novel anti-parkinsonian agents
WO2008111956A3 (en) Fatty acid oxidation inhibitors treating hyperglycemia and related disorders
WO2005058813A3 (en) Thiodiazolidinedione, oxazolidinedione and diazolidinedione derivatives and their use as antidiabetic agents
Prasad et al. Synthesis of some 4’-amino chalcones and their antiinflammatory and antimicrobial activity
WO2005100331A3 (en) Antidiabetic agents
CN1630653A (en) Pyrazolyl-substituted heterocycles and their use as phytosanitary products
JP2014237589A (en) Cyclic amine compound and pest controlling agent
ES2156574A1 (en) Thiazolidinedione derivatives as antidiabetic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase